Biographies

E-mail this page

(All fields required)

Recipient's email address

Please enter a valid email.

Your name

Please enter your name.

Your email address

Please enter a valid email.

Find another Doctor or Researcher

High Res

Brian D. Weiss, MD

Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute

Cincinnati Children's Principal Investigator, New Approaches to Neuroblastoma Therapy Consortium

Medical Director, Neuroblastoma Program

Associate Professor, UC Department of Pediatrics

Phone: 513-636-9863

Fax: 513-636-3549

Email: brian.weiss@cchmc.org

Show All

Specialties

Targeted agents for neurofibromatosis type 1-related malignancies; high-risk neuroblastoma and 131I-MIBG treatment of neuroblastoma; new approaches to targeting and killing neuroblastoma cells

Education and Training

MD: Northwestern University Medical School, Chicago, IL, 1993.

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007

Publications

View PubMed Publications

Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-related plexiform neurofibroma to High-Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90.

Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.

Weiss B, Geiger H, Davies SM. Possible leukemogenic potential of temozolomide. Pediatr Blood Cancer. 2009 Apr;52(4):553.

Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009 Mar;33(3):355-62.

Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5418-25.

Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006 Apr 1;107(7):3010-1.